Jane Kendrew

4.1k total citations · 1 hit paper
33 papers, 2.7k citations indexed

About

Jane Kendrew is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Kendrew has authored 33 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 19 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Kendrew's work include Angiogenesis and VEGF in Cancer (22 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and HER2/EGFR in Cancer Research (8 papers). Jane Kendrew is often cited by papers focused on Angiogenesis and VEGF in Cancer (22 papers), PI3K/AKT/mTOR signaling in cancer (8 papers) and HER2/EGFR in Cancer Research (8 papers). Jane Kendrew collaborates with scholars based in United Kingdom, France and Singapore. Jane Kendrew's co-authors include Stephen R. Wedge, Laurent Hennequin, Jon Curwen, Donald Ogilvie, Elaine S. E. Stokes, Michael Dukes, Andrew P. Thomas, Brenda J Curry, P.F. Wadsworth and Graham H.P. Richmond and has published in prestigious journals such as Cell Metabolism, Cancer Research and Oncogene.

In The Last Decade

Jane Kendrew

33 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

2002 702 citations Stephen R. Wedge, Donald Ogilvie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Kendrew United Kingdom	22	1.5k	1.1k	638	561	313	33	2.7k
Jon Curwen United Kingdom	20	1.5k 1.0×	1.0k 0.9×	634 1.0×	406 0.7×	146 0.5×	31	2.7k
Dana D. Hu‐Lowe United States	17	1.8k 1.1×	1.0k 0.9×	798 1.3×	778 1.4×	340 1.1×	34	3.0k
Laurent Hennequin France	22	1.5k 1.0×	973 0.9×	500 0.8×	341 0.6×	149 0.5×	52	2.7k
Peter F. Lebowitz United States	24	2.3k 1.5×	1.8k 1.6×	411 0.6×	422 0.8×	149 0.5×	40	3.2k
Randall Schreck United States	9	1.5k 1.0×	686 0.6×	318 0.5×	469 0.8×	102 0.3×	13	2.3k
Jonathan M. Yingling United States	26	2.7k 1.7×	1.3k 1.1×	502 0.8×	385 0.7×	166 0.5×	49	3.6k
Kyle D. Holen United States	31	1.1k 0.7×	1.8k 1.7×	479 0.8×	372 0.7×	227 0.7×	126	3.2k
Mari Iida United States	30	1.5k 1.0×	1.3k 1.2×	620 1.0×	429 0.8×	294 0.9×	62	2.8k
Edward Rosfjord United States	19	938 0.6×	1.0k 0.9×	383 0.6×	271 0.5×	358 1.1×	39	1.9k
Tokuzo Arao Japan	38	2.2k 1.4×	1.4k 1.3×	1.1k 1.7×	771 1.4×	212 0.7×	90	3.7k

Countries citing papers authored by Jane Kendrew

Since Specialization

Citations

This map shows the geographic impact of Jane Kendrew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Kendrew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Kendrew more than expected).

Fields of papers citing papers by Jane Kendrew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Kendrew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Kendrew. The network helps show where Jane Kendrew may publish in the future.

Co-authorship network of co-authors of Jane Kendrew

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Kendrew. A scholar is included among the top collaborators of Jane Kendrew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Kendrew. Jane Kendrew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hargreaves, Adam, Alison Bigley, Sally Price, Jane Kendrew, & Simon T. Barry. (2017). Automated image analysis of intra‐tumoral and peripheral endocrine organ vascular bed regression using ‘Fibrelength’ as a novel structural biomarker. Journal of Applied Toxicology. 37(8). 902–912. 2 indexed citations

Pommier, Aurélien, Matthew R. Farren, Bhavika Patel, et al.. (2015). Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer. Cell Metabolism. 23(1). 77–93. 15 indexed citations

Smith, Neil R., Dawn Baker, Matthew R. Farren, et al.. (2013). Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy. Clinical Cancer Research. 19(24). 6943–6956. 111 indexed citations

Kendrew, Jane, Rajesh Odedra, Armelle Logié, et al.. (2013). Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemotherapy and Pharmacology. 71(4). 1021–1032. 20 indexed citations

Jenkins, David W., Sarah J. Ross, Margaret H. Veldman-Jones, et al.. (2012). MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo. Molecular Cancer Therapeutics. 11(8). 1650–1660. 47 indexed citations

Eberlein, Catherine A., Jane Kendrew, Karen McDaid, et al.. (2012). A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo. Oncogene. 32(37). 4406–4416. 74 indexed citations

Brave, Sandra R., Kirsty Ratcliffe, Zena Wilson, et al.. (2011). Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family. Molecular Cancer Therapeutics. 10(5). 861–873. 72 indexed citations

Brown, Jeffrey L., Zhe Cao, Maria Pinzon-Ortiz, et al.. (2010). A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models. Molecular Cancer Therapeutics. 9(1). 145–156. 113 indexed citations

Jürgensmeier, Juliane M., Jane Kendrew, Rajesh Odedra, et al.. (2010). Abstract 1372: Cediranib alone and in combination with mechanistically distinct antitumor therapies in vivo. Cancer Research. 70(8_Supplement). 1372–1372. 2 indexed citations

10.

Bradley, Daniel P., et al.. (2007). Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast‐enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol). NMR in Biomedicine. 21(1). 42–52. 34 indexed citations

11.

Ballard, Peter, Robert H. Bradbury, Craig S. Harris, et al.. (2006). Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics. Bioorganic & Medicinal Chemistry Letters. 16(18). 4908–4912. 29 indexed citations

12.

McKillop, D., Simon P. Guy, Jane Kendrew, et al.. (2006). Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica. 36(1). 29–39. 20 indexed citations

13.

Hennequin, Laurent, Peter Ballard, Bénédicte Delouvrié, et al.. (2006). Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(10). 2672–2676. 22 indexed citations

14.

Wedge, Stephen R., Jane Kendrew, Jon Curwen, et al.. (2004). The VEGF receptor tyrosine kinase inhibitor AZD2171 inhibits VEGF signaling, angiogenesis, and tumor growth in vivo. Cancer Research. 64. 1052–1052. 7 indexed citations

15.

Checkley, D., Jean Tessier, Jane Kendrew, John C. Waterton, & Stephen R. Wedge. (2003). Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. British Journal of Cancer. 89(10). 1889–1895. 102 indexed citations

16.

Checkley, D., Jean Tessier, Stephen R. Wedge, et al.. (2003). Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magnetic Resonance Imaging. 21(5). 475–482. 48 indexed citations

17.

Whittles, C.E., Tristan Pocock, Stephen R. Wedge, et al.. (2002). ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor-Receptor-2 Tyrosine Kinase Activity. Microcirculation. 9(6). 513–522. 5 indexed citations

18.

Whittles, C.E., Tristan Pocock, Stephen R. Wedge, et al.. (2002). ZM323881, a Novel Inhibitor of Vascular Endothelial Growth Factor‐Receptor‐2 Tyrosine Kinase Activity. Microcirculation. 9(6). 513–522. 75 indexed citations

19.

Hennequin, Laurent, Elaine S. E. Stokes, Andrew P. Thomas, et al.. (2002). Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors. Journal of Medicinal Chemistry. 45(6). 1300–1312. 254 indexed citations

20.

Miotla, Jadwiga M., Rose A. Maciewicz, Jane Kendrew, Marc Feldmann, & Ewa Paleolog. (2000). Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis. Laboratory Investigation. 80(8). 1195–1205. 142 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact